((自动化翻译由路透提供，请见免责声明 ))
1月7日 - ** 疗法开发商Immuneering 股价盘前上涨101.7%至4.76美元
** 该公司称，在一项针对胰腺癌患者的中期试验 (link) 中，其疗法 IMM-1-104 与吉西他滨的联合治疗显示出 43% 的总体反应率
** IMRX 将扩大试验范围，除现有的三个联合治疗组外，今年还将增加三个联合治疗组。
** 该公司表示，预计 2025 年第二季度将获得更多试验数据
** 截至上次收盘，股价在过去 12 个月中下跌了 64.8
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.